First-in-man trial of β3-adrenoceptor agonist treatment in chronic heart failure - impact on diastolic function

Keyphrases

• Chronic Heart Failure 100%
• Agonist Treatment 100%
• Diastolic Dysfunction 100%
• Diastolic Function 100%
• Adrenoceptor Agonist 100%
• Failure Impact 100%
• First-in-human 100%
• Placebo 75%
• Echocardiography 50%
• Reduced Ejection Fraction 50%
• Cardiac Computed Tomography 50%
• Mirabegron 50%
• N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) 50%
• Ischemic Heart Disease 25%
• Heart Failure 25%
• Left Ventricular Ejection Fraction 25%
• Ca2+ 25%
• Sodium 25%
• Group by 25%
• Na + 25%
• Double-blind Trial 25%
• Previous Literature 25%
• Heart Failure Therapy 25%
• Adrenoceptors 25%
• Cytosolic Calcium 25%
• Clinically Significant Change 25%
• New York Heart Association 25%
• Left Atrial Volume Index 25%
• β3-adrenoceptor 25%
• Sodium-calcium Exchanger 25%
• Sodium Gradient 25%
• Calcium Efflux 25%
• Follow-up Data 25%
• Organ Congestion 25%

Medicine and Dentistry

• Diastolic Dysfunction 100%
• Diastolic Function 100%
• Congestive Heart Failure 100%
• Sympathomimetic Drug 100%
• Placebo 75%
• Amino Terminal Sequence 50%
• Natriuretic Factor 50%
• Isotopes of Calcium 50%
• Echocardiography 50%
• Ejection Fraction 50%
• Cardiac Computed Tomography 50%
• Mirabegron 50%
• Sodium 50%
• Biological Marker 25%
• Heart Left Ventricle Ejection Fraction 25%
• Ischemic Heart Disease 25%
• Adrenergic Receptor 25%
• Sodium Ion 25%
• Calcium Transport 25%
• Sodium Calcium Exchange Protein 25%
• Beta 3 Adrenergic Receptor Stimulating Agent 25%
• Left Atrial Volume 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Congestive Heart Failure 100%
• Diastolic Dysfunction 100%
• Adrenergic Receptor Stimulating Agent 100%
• Placebo 75%
• Natriuretic Factor 50%
• Mirabegron 50%
• Sodium 50%
• Ischemic Heart Disease 25%
• Biological Marker 25%
• Effusion 25%
• Adrenergic Receptor 25%
• Sodium Ion 25%
• Sodium Calcium Exchange Protein 25%
• Beta 3 Adrenergic Receptor Stimulating Agent 25%